Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss ( ≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.

Source: Primary Care Diabetes - May 23, 2023 Category: Primary Care Authors: Jos é Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, María Teresa Pérez-Álvarez, Belén Ponce-Piñón, Marlén Fernández-Silva, Marta Rodríguez-Barreiro, Mercedes Pereira-Pía, Jose Manuel Iglesias-Moreno, Mar Gago-García, Raquel Source Type: research